Kenya and Ethiopia will be among three countries that a leading healthcare company will launch a portfolio of medicines to treat chronic diseases in low- and low-middle-income countries. Vietnam is the other country that company Novartis is launching the portfolio of 15 medicines.
The portfolio addresses cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer. It will be offered to governments, non-governmental organisations (NGOs) and other public-sector healthcare providers for US$1 per treatment, per month.
“Novartis Access is a natural extension of two important contributions our company makes to society: developing innovative medicines that help people fight disease and working to get them to as many people as possible,” said Joerg Reinhardt, Chairman of the Board of Novartis.
He said that this programme took a novel approach to addressing the rising tide of chronic diseases in parts of the world where people often have limited access to healthcare. “We know we will need to keep an open mindset and learn as we progress on this journey.”
The Novartis Access portfolio includes patented and generic Novartis medicines. The products included in the Novartis Access product portfolio have been selected based on the World Health Organization’s Essential Medicines List and are among the most commonly prescribed medicines in these countries.
Novartis expects this new approach to be commercially sustainable over the long term, enabling continuous support in those regions. Each year, approximately 28 million people die from chronic noncommunicable diseases (NCDs) in low- and middle-income countries, representing 75 percent of deaths from NCDs globally. y 2025, the WHO projects that 75 percent of all deaths will be due to NCDs2, mostly due to the rapid increase of NCDs in poverty-stricken areas.